CTOs on the Move

Groninger USA

www.groningerusa.com

 
Groninger USA is a Charlotte, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Friendship Health and Rehab Center

Friendship Health and Rehab Center is a Roanoke, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Dax and Lindsay: Thermal Reconditioning Specialists

Dax and Lindsay: Thermal Reconditioning Specialists is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Bioanalytical Systems

BASi provides world-class research to the pharmaceutical industry worldwide. Established in 1974, we offer an extensive array of contract laboratory services and also manufacture more than 30 different scientific instruments. At BASi we focus on developing innovative services and products that increase efficiency and reduce costs associated with taking new drugs to market.

Agenus

Agenus is an immuno-oncology company driven by innovation and speed. Our goal is to treat cancers with novel combinations utilizing our unique portfolio of checkpoint antibodies, tumor microenvironment modifiers, vaccines and adjuvants. In addition to a broad portfolio, we have an accomplished team of scientists, novel technology platforms and fully-integrated end-to-end capabilities from discovery to GMP manufacturing. With our remarkable combination of science and people, we believe that we are uniquely positioned to bring curative treatments to cancer patients.

Spruce Biosciences

Spruce is a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need. Our wholly-owned product candidate, tildacerfont, is a CRF1 receptor antagonist currently in late-stage trials in adult patients with classic congenital adrenal hyperplasia (CAH), with a planned Phase 2 trial in pediatric classic CAH. We aim to advance the treatment paradigm for classic CAH with a well-tolerated, non-steroidal approach designed to offer markedly improved disease control and reduced steroid burden for patients. Tildacerfont may also benefit patients with other disorders characterized by elevated levels of or hyperresponsiveness to adrenocorticotropic hormone (ACTH), a hormone involved in the production of cortisol, including a rare form of polycystic ovary syndrome (PCOS).